Introduction {#s1}
============

Obesity is classified by the World Health Organisation as an epidemic, with an estimate of over 600 million individuals affected worldwide \[[@R01]\]. Further, New Zealand has the third highest rate of obesity in the world \[[@R02]\]. The condition poses a significant burden on healthcare, and is associated with a plethora of diseases, including metabolic diseases, cardiovascular diseases and cancer. That certain ethnicities, including indigenous populations, are over-represented in obesity and metabolic disease-related statistics is a well-recognized public health issue \[[@R03]\]. In New Zealand, the rate of obesity in Maori adults is double the rate of that in non-Maori individuals \[[@R02]\] and Maori people have poorer health outcomes \[[@R04]\]. Similarly, other indigenous populations around the globe, such as Pima Indians in the USA \[[@R05], [@R06]\], aboriginal Canadians \[[@R07], [@R08]\], aboriginal Australians \[[@R9]\] and aboriginal Taiwanese\[[@R10]\], have higher prevalence of obesity and poorer health outcomes compared to the general population. These findings place the health disparities among indigenous populations at the forefront, highlighting the need of better understanding the underlying pathogenetic mechanisms in order to develop potential ethnicity-specific preventative and therapeutic measures.

The gut and the pancreas are crucial players in metabolic processes due to the hormones secreted by these organs that regulate metabolic homeostasis \[[@R11]\]. Alterations in circulating levels of gut and pancreatic hormones can disrupt metabolic homeostasis in several ways and, in particular, result in excess adiposity and glucose derangement \[[@R12]\]. Another factor that contributes to impaired metabolic homeostasis is chronic low-grade inflammation characteristic of obesity and impaired glucose tolerance \[[@R13], [@R14]\]. Recent studies show that hormones such as insulin, amylin, pancreatic polypeptide (PP) and ghrelin are significantly associated with pro-inflammatory cytokines namely interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1) and tumour necrosis factor-α (TNFα) in patients with impaired metabolic homeostasis \[[@R15], [@R16]\].

Socioeconomic inequality and lifestyle factors explain (to some extent) ethnic health disparity \[[@R17], [@R18]\]; however, ethnicity-specific differences in hormone levels are suggested to be a contributing factor as well \[[@R19]-[@R21]\]. Altered gut and pancreatic hormone levels may predispose certain ethnic groups to obesity and metabolic disorders. Evidence to date, albeit limited, shows that genetic variation and single nucleotide polymorphisms can contribute to altered circulating levels of gut and pancreatic hormones \[[@R22]-[@R24]\]. Findings from the study by Koska et al \[[@R20]\] showed that Pima Indians have increased PP levels. Studies by Harris et al \[[@R25]\] and Karim et al \[[@R21]\] showed that African Americans have altered insulin and C-peptide levels. However, whether New Zealand Maori have a unique hormone and cytokine profile that predisposes them to higher risk of obesity and diabetes has never been investigated.

The aim of this study was to investigate profile of gut hormones, pancreatic hormones and pro-inflammatory cytokines in Maori versus non-Maori individuals.

Patients and Methods {#s2}
====================

Study design {#s2a}
------------

This was a *post-hoc* analysis of the DORADO study - a cross-sectional study of individuals with a history of acute pancreatitis (defined prospectively based on international guidelines \[[@R26]\]). The study protocol was granted ethical approval by the Health and Disability Committee (13/STH/182). The protocol of the study was described in detail elsewhere \[[@R27]-[@R29]\]. Ethnicity of participants was self-reported and grouped into Maori and non-Maori. Participants identified as Maori were contacted to confirm Maori lineage by obtaining the ethnicity of all four grandparents.

Sample acquisition, storage and laboratory assays {#s2b}
-------------------------------------------------

Fasting (for at least 8 h) venous blood was collected for all participants by a certified phlebotomist at the internationally accredited New Zealand medical laboratory, Lab Plus, at Auckland City Hospital. Appropriate inhibitor (aprotinin or dipeptidyl peptidase IV) was added to each tube, and the blood was centrifuged at 4 °C for 7.5 min at 4,000 *g*. Plasma was separated, aliquoted and stored at -80 °C until use. Fasting blood glucose, insulin and glycated haemoglobin A1c (HbA1c) were analyzed at Lab-Plus using enzymatic colourimetric assay (F. Hoffman-La Roche Ltd), chemiluminescence sandwich immunoassay (Roche Diagnostics NZ Ltd) and boronate affinity chromatography assay (Trinity Biotech, Ireland), respectively. Amylin, C-peptide, gastric inhibitory peptide (GIP), glucagon, PP, peptide YY (PYY), IL-6, MCP-1 and TNFα were measured using MILLIPLEX MAP Human metabolic hormone magnetic bead panel based on the Lumixe xMAP (Luminex) technology. Results were quantified (ng/mL) based on fluorescent reporter signals recorded by the Luminex xPOTENT software (MILLIPLEX Analyst 5.1). Somatostatin, cholecystokinin, gastrin, glicentin, glucagon-like peptide (GLP)-1, GLP-2, oxyntomodulin and secretin were measured using Merck-Millipore enzyme-linked immunosorbent assay (ELISA) kits. Results were quantified using Rayto Microplate Reader (V-2100C; Santa Fe, Granada, Spain), with absorbance of 405 - 630 nm. All hormones and pro-inflammatory cytokines were reported as ng/mL, except for glicentin and gastrin, which were reported as pmol/mL and pg/mL respectively.

Definitions {#s2c}
-----------

Etiology was categorized as alcohol, biliary or other (e.g. hypertriglyceridemia, idiopathic pancreatitis, pancreas divisum). Body mass index (BMI, kg/m^2^) was determined using a digital scale with stadiometer (Health o meter^®^ Professional, 2013, ©Pelstar, LLC, IL, USA). Participants were categorized into three groups: 1) healthy (18.5 - 24.9 kg/m^2^), 2) overweight (25 - 29.9 kg/m^2^) and 3) obese (≥ 30.0 kg/m^2^) in accordance to the National Institute of Health and World Health Organisation guidelines \[[@R30], [@R31]\]. Diabetes mellitus (DM) status was determined based on fasting blood glucose (FBG) ≥ 7.0 mmol/L and/or HbA1c ≥ 49 mmol/mol at the time of study \[[@R32]\]. Time since pancreatitis was defined as number of months since first hospital admission due to acute pancreatitis to the time of blood collection. Recurrence: individuals determined with recurrent acute pancreatitis were admitted with at least one episode of confirmed acute pancreatitis since their first admission with acute pancreatitis to their time of participation in the study. Severity of acute pancreatitis: was defined in accordance with the 2012 Determinant-Based Classification \[[@R33], [@R34]\].

Statistical analyses {#s2d}
--------------------

Statistical analyses were performed using SPSS 23.0 for Mac OSX (IBM Corp., 2015). Mann-Whitney *U* test and Fisher's exact tests were used to assess differences in baseline characteristics for continuous and categorical variables, respectively. All data were reported as either median and interquartile range (IQR) or frequencies. Having met all statistical assumptions, binary logistic regression was used to investigate the relationship between gut hormones, pancreatic hormones and pro-inflammatory cytokines in Maori versus non-Maori participants. C-peptide was log transformed for the analyses. Extreme data points were omitted to reduce the influence of outliers and to obtain the most robust and conservative output. Each peptide was analyzed as the independent variable in one unadjusted model and four adjusted models. In the unadjusted model, the association between participant's ethnicity and peptide levels was investigated. Model 1 was adjusted for age and sex; model 2 was adjusted for age, sex, smoking, exercise, BMI and DM status; model 3 was adjusted for pancreatitis-related factors, including etiology, recurrence, time since pancreatitis and severity of acute pancreatitis; while model 4 was adjusted for all of the factors mentioned above. All data are reported as β coefficients and odds ratio (OR) with corresponding 95% confidence intervals (CIs). P \< 0.05 was accepted as statistically significant in all analyses.

Results {#s3}
=======

Patient characteristics {#s3a}
-----------------------

A total of 93 individuals were recruited into the study, of who eight (8.6%) were Maori and 85 (91.4%) were non-Maori. The median (IQR) age of the entire cohort was 53 (42 - 65) years and 57 (60%) of all participants were male. The other baseline characteristics for all study participants are shown in [Table 1](#T1){ref-type="table"}.

###### Baseline Participant Characteristics

                             Total                Maori                Non-Maori            P
  -------------------------- -------------------- -------------------- -------------------- -------
  No. of patients            93                   8                    85                   0.372
  Age, years                 53 (42 - 65)         52 (47 - 64)         53 (42 - 65)         0.978
  Sex                                                                                       
    Male                     57                   4                    53                   0.372
    Female                   36                   4                    32                   
  Smoking status                                                                            0.339
    Smoker                   69                   5                    64                   
    Non-smoker               24                   3                    21                   
  Exercise                                                                                  0.548
    Yes                      61                   2                    59                   
    No                       32                   6                    26                   
  Body mass index, kg/m^2^   27.5 (24.6 - 30.8)   30.6 (26.1 - 38.0)   27.4 (24.4 - 30.6)   0.117
  Diabetes mellitus                                                                         0.205
    Yes                      10                   2                    8                    
    No                       83                   6                    77                   
  Etiology                                                                                  0.465
    Biliary                  43                   3                    40                   
    Alcohol                  21                   1                    20                   
    Other                    29                   4                    25                   
  Recurrence                                                                                0.452
    Yes                      28                   3                    25                   
    No                       65                   5                    60                   
  Severity                                                                                  0.562
    Mild                     73                   6                    67                   
    Moderate                 14                   2                    12                   
    Severe/critical          6                    0                    6                    

Data presented as median (interquartile range) or count values.

Gut hormones {#s3b}
------------

Ghrelin was significantly higher among Maori participants with a median (IQR) of 17.76 (7.21 - 42.13) ng/mL and 8.38 (4.24 - 14.36) ng/mL in non-Maori participants (P = 0.016). The comparison of distribution of ghrelin levels between the two groups are illustrated in [Figure 1](#F1){ref-type="fig"}. Ghrelin was significantly higher in Maori participants across all five models with the highest OR (95% CI; P value) reported in model 4 with an OR of 1.111 (1.012 - 1.219; P = 0.027). Glicentin was significantly higher in Maori participants in four models with the highest OR reported in model 2 with an OR of 1.104 (1.011 - 1.206; P = 0.027). Cholecystokinin, gastrin, GIP, GLP-1, GLP-2, PYY, oxyntomodulin and secretin were not found to be significantly associated with ethnicity in any of the five models ([Table 2](#T2){ref-type="table"}).

![Ghrelin levels in Maori versus non-Maori.](gr-11-280-g001){#F1}

###### Gut Hormones in Maori Versus Non-Maori

  Gut hormones                     Model        Regression coefficient (β)   OR       95% CI      P          
  -------------------------------- ------------ ---------------------------- -------- ----------- ---------- -------
  Cholecystokinin                  Unadjusted   0.846                        2.331    0.448       12.126     0.314
  1                                0.836        2.308                        0.446    11.943      0.319      
  2                                0.643        1.903                        0.351    10.333      0.456      
  3                                0.606        1.833                        0.307    10.934      0.506      
  4                                0.362        1.437                        0.186    11.081      0.728      
  Ghrelin                          Unadjusted   0.075                        1.078    1.022       1.136      0.005
  1                                0.075        1.078                        1.021    1.138       0.007      
  2                                0.088        1.092                        1.023    1.166       0.008      
  3                                0.079        1.082                        1.012    1.157       0.021      
  4                                0.105        1.111                        1.012    1.219       0.027      
  Gastric inhibitory polypeptide   Unadjusted   0.005                        1.005    0.995       1.014      0.354
  1                                0.005        1.005                        0.995    1.015       0.299      
  2                                0.005        1.005                        0.994    1.017       0.371      
  3                                0.004        1.004                        0.993    1.014       0.505      
  4                                0.009        1.009                        0.995    1.023       0.229      
  Glicentin                        Unadjusted   0.077                        1.080    1.017       1.148      0.013
  1                                0.081        1.084                        1.018    1.155       0.012      
  2                                0.099        1.104                        1.011    1.206       0.027      
  3                                0.076        1.079                        1.009    1.153       0.027      
  4                                0.083        1.086                        0.983    1.200       0.103      
  Glucagon-like peptide-1          Unadjusted   0.211                        1.235    0.937       1.629      0.135
  1                                0.223        1.250                        0.922    1.694       0.151      
  2                                0.221        1.247                        0.894    1.740       0.193      
  3                                0.283        1.327                        0.956    1.843       0.091      
  4                                0.415        1.515                        0.962    2.387       0.073      
  Glucagon-like peptide-2          Unadjusted   0.086                        1.090    0.969       1.226      0.152
  1                                0.081        1.084                        0.964    1.220       0.178      
  2                                0.083        1.086                        0.946    1.247       0.241      
  3                                0.089        1.093                        0.957    1.248       0.191      
  4                                0.099        1.104                        0.901    1.353       0.341      
  Oxyntomodulin                    Unadjusted   -0.015                       0.986    0.913       1.044      0.618
  1                                -0.015       0.985                        0.930    1.043       0.606      
  2                                -0.022       0.978                        0.921    1.038       0.466      
  3                                -0.033       0.967                        0.911    1.027       0.279      
  4                                -0.042       0.959                        0.895    1.028       0.238      
  Peptide YY                       Unadjusted   0.003                        1.003    0.997       1.009      0.292
  1                                0.004        1.004                        0.998    1.010       0.226      
  2                                0.004        1.004                        0.998    1.011       0.217      
  3                                0.005        1.005                        0.998    1.011       0.137      
  4                                0.006        1.006                        0.999    1.013       0.111      
  Secretin                         Unadjusted   2.841                        17.132   0.243       1208.835   0.191
  1                                2.871        17.663                       0.252    1238.300    0.185      
  2                                3.511        33.480                       0.275    4071.267    0.152      
  3                                1.286        3.618                        0.031    427.932     0.597      
  4                                3.233        25.343                       0.064    10080.329   0.290      

OR: odds ratio; CI: confidence interval. OR indicate membership to Maori. Model 1 for all gut hormones was adjusted for age and sex. Model 2 for all gut hormones was adjusted for age, sex, smoking, exercise, BMI and diabetes mellitus. Model 3 for all gut hormones was adjusted for etiology, recurrence, time since pancreatitis and severity. Model 4 for all gut hormones was adjusted for age, sex, smoking, exercise, BMI, diabetes mellitus, etiology, recurrence, time since pancreatitis and severity.

Pancreatic hormones {#s3c}
-------------------

Pancreatic polypeptide was significantly higher in Maori participants with a median (IQR) of 184.51 (63.87 - 427.04) ng/mL and 45.69 (15.91 - 109.26) ng/mL in non-Maori participants (P = 0.008). The comparison of distribution of PP levels between the two groups are illustrated in [Figure 2](#F2){ref-type="fig"}. Pancreatic polypeptide was significantly higher in Maori participants consistently across all five models with the highest OR in model 4 with an OR (95% CI; P value) of 1.013 (1.002 - 1.025; P = 0.024). Amylin was significantly decreased in Maori participants in two models with the lowest OR in model 4 with an OR of 0.234 (0.059 - 0.937; P = 0.040). C-peptide, glucagon, insulin and somatostatin were not found to be significantly associated with ethnicity in any of the five models ([Table 3](#T3){ref-type="table"}).

![Pancreatic polypeptide levels in Maori versus non-Maori.](gr-11-280-g002){#F2}

###### Pancreatic Hormones in Maori Versus Non-Maori

  Pancreatic hormone       Model        Regression coefficient (β)   OR      95% CI     P        
  ------------------------ ------------ ---------------------------- ------- ---------- -------- -------
  Amylin                   Unadjusted   -0.378                       0.685   0.375      1.252    0.219
  1                        -0.388       0.678                        0.363   1.267      0.223    
  2                        -0.934       0.393                        0.157   0.985      0.046    
  3                        -0.432       0.649                        0.319   1.323      0.234    
  4                        -1.451       0.234                        0.059   0.937      0.040    
  C-peptide                Unadjusted   -0.476                       0.621   0.083      4.656    0.643
  1                        -0.595       0.551                        0.063   4.799      0.590    
  2                        -0.593       0.553                        0.054   5.632      0.617    
  3                        -0.782       0.457                        0.043   4.860      0.516    
  4                        -3.209       0.040                        0.001   2.327      0.121    
  Glucagon                 Unadjusted   -0.001                       0.999   0.983      1.016    0.900
  1                        -0.001       0.999                        0.982   1.017      0.926    
  2                        -0.001       0.999                        0.980   1.019      0.929    
  3                        -0.003       0.997                        0.978   1.016      0.731    
  4                        -0.002       0.998                        0.976   1.021      0.869    
  Insulin                  Unadjusted   0.006                        1.006   0.996      1.017    0.248
  1                        0.006        1.006                        0.996   1.016      0.231    
  2                        0.004        1.004                        0.989   1.020      0.619    
  3                        0.010        1.011                        0.993   1.029      0.246    
  4                        0.006        1.006                        0.985   1.027      0.593    
  Pancreatic polypeptide   Unadjusted   0.011                        1.011   1.003      1.018    0.004
  1                        0.011        1.011                        1.004   1.018      0.003    
  2                        0.011        1.011                        1.003   1.019      0.007    
  3                        0.011        1.011                        1.003   1.019      0.008    
  4                        0.013        1.013                        1.002   1.025      0.024    
  Somatostatin             Unadjusted   1.394                        4.031   0.443      36.648   0.216
  1                        1.386        4.001                        0.438   36.558     0.219    
  2                        1.750        5.753                        0.535   61.834     0.149    
  3                        2.189        8.926                        0.555   143.507    0.122    
  4                        3.268        26.253                       0.683   1009.537   0.079    

OR: odds ratio; CI: confidence interval. OR indicate for membership to Maori. Model 1 for all pancreatic hormones was adjusted for age and sex. Model 2 for all pancreatic hormones was adjusted for age, sex, smoking, exercise, BMI and diabetes mellitus. Model 3 for all pancreatic hormones was adjusted for etiology, recurrence, time since pancreatitis and severity. Model 4 for all pancreatic hormones was adjusted for age, sex, smoking, exercise, BMI, diabetes mellitus, etiology, recurrence, time since pancreatitis and severity. C-peptide values were log~10~ transformed.

Pro-inflammatory cytokines {#s3d}
--------------------------

IL-6 was significantly higher in Maori participants with a median (IQR) of 11.21 (1.93 - 50.47) ng/mL and 1.87 (0.26 - 6.72) ng/mL in non-Maori participants (P = 0.013). The comparison of distribution of IL-6 levels between the two groups are illustrated in [Figure 3](#F3){ref-type="fig"}. IL-6 was significantly higher in Maori participants consistently across all five models with the highest OR in model 4 with an OR (95% CI; P value) of 1.256 (1.016 - 1.554; P = 0.035). MCP-1 and TNFα were not found to be significantly associated with ethnicity in any of the five models ([Table 4](#T4){ref-type="table"}).

![Interleukin-6 levels in Maori versus non-Maori.](gr-11-280-g003){#F3}

###### Pro-Inflammatory Cytokines in Maori Versus Non-Maori

  Cytokies                             Model        Regression coefficient (β)   OR      95% CI   P       
  ------------------------------------ ------------ ---------------------------- ------- -------- ------- -------
  Interleukin-6                        Unadjusted   0.110                        1.117   1.012    1.233   0.029
  1                                    0.199        1.220                        1.048   1.422    0.011   
  2                                    0.197        1.218                        1.031   1.438    0.020   
  3                                    0.208        1.231                        1.046   1.448    0.012   
  4                                    0.228        1.256                        1.016   1.554    0.035   
  Monocyte chemoattractant protein-1   Unadjusted   0.005                        1.005   0.997    1.014   0.227
  1                                    0.007        1.007                        0.998   1.017    0.134   
  2                                    0.008        1.008                        0.998   1.019    0.117   
  3                                    0.005        1.005                        0.997   1.014    0.223   
  4                                    0.012        1.012                        0.999   1.026    0.070   
  Tumour necrosis factor-α             Unadjusted   0.084                        1.088   0.945    1.253   0.242
  1                                    0.096        1.101                        0.954   1.271    0.189   
  2                                    0.084        1.088                        0.929   1.273    0.294   
  3                                    0.100        1.105                        0.936   1.304    0.239   
  4                                    0.186        1.204                        0.963   1.506    0.103   

OR: odds ratio; CI: confidence interval. OR indicate membership to Maori. Model 1 for all cytokines was adjusted for age and sex. Model 2 for all cytokines was adjusted for age, sex, smoking, exercise, BMI and diabetes mellitus. Model 3 for all cytokines was adjusted for etiology, recurrence, time since pancreatitis and severity. Model 4 for all cytokines was adjusted for age, sex, smoking, exercise, BMI, diabetes mellitus, etiology, recurrence, time since pancreatitis and severity.

Discussion {#s4}
==========

This is the first study to investigate a comprehensive panel of gut hormones, pancreatic hormones and pro-inflammatory cytokines in Maori individuals. Multi-level statistical modelling was used to determine differences in the levels of studied hormones and pro-inflammatory cytokines between Maori and non-Maori participants and statistical models were adjusted for demographic, metabolic and pancreatitis-related factors in order to obtain the most robust results. Maori ethnicity was significantly associated (consistently across all statistical models) with elevated levels of ghrelin, PP and IL-6 in both unadjusted and adjusted analyses (controlling for BMI, DM status, pancreatitis-related characteristics and other covariates). These findings provide the first preliminary evidence that Maori individuals may differ to non-Maori individuals in hormone makeup, which may contribute towards understanding the pathogenesis of obesity in this ethnic group.

The first key finding of this study was that Maori participants had significantly higher fasting ghrelin levels. Ghrelin is a 28 amino acid peptide with a N-octanylated serine residue and an endogenous ligand of the growth hormone secretagogue receptor, which stimulates the release of the growth hormone \[[@R35], [@R36]\]. Commonly referred to as the "hunger hormone" \[[@R37], [@R38]\], ghrelin is involved in regulating energy consumption across the gut-brain axis by stimulating appetite \[[@R36], [@R39]\]. Elevated circulating ghrelin is seen in the Panders-Willis syndrome - a genetic condition pre-disposing individuals to obesity and hyperphagia \[[@R40], [@R41]\]. Given the orexigenic effect of ghrelin, elevated fasting levels of this hormone in Maori individuals suggests that ghrelin may play an important role in regulating energy balance, whereby increased levels contribute to higher food consumption and increased propensity towards excessive fat storage, leading to obesity.

The second key finding of this study was that Maori participants had significantly elevated PP levels compared to the non-Maori participants. Pancreatic polypeptide is a member of the PP-fold family and is a straight-chain of 36 amino acid peptide \[[@R42]\] secreted primarily by PP cells located in the pancreatic islets of Langerhans \[[@R43]\]. Pancreatic polypeptide secretion is controlled by the vagus nerve, and its secretion is conventionally thought to be stimulated only postprandially \[[@R35], [@R43], [@R44]\]. However, a recent study by Arosio et al \[[@R45]\] showed that intravenous administration of ghrelin in healthy subjects resulted in increased fasting levels of PP. Pancreatic polypeptide is also associated with adiposity and has been demonstrated to be a biomarker of abdominal adiposity \[[@R46]\] as well as a biomarker for visceral and intra-hepatocellular fat content in overweight individuals \[[@R47]\]. Pancreatic polypeptide levels are known to differ between ethnicities, where in Pima Indians PP is elevated (both in fasting state and postprandially) compared to Caucasians \[[@R48], [@R49]\]. Further, a study by Koska et al \[[@R20]\] found that increased levels of fasting PP in Pima Indian males indicate a higher risk of future weight gain. Given these findings, elevated circulating PP levels are indicative of a greater risk of obesity, mechanistically thought to be caused by increased visceral parasympathetic activity \[[@R48]\]. In the present study, fasting PP was significantly higher in Maori (even after controlling for factors such as BMI, DM status and other covariates), which suggests that PP levels may be innately higher in Maori individuals \[[@R46], [@R50]\]. Further, PP may also be elevated in Maori in response to elevated circulating ghrelin levels reported above \[[@R45]\]. Based on these findings, we hypothesize that increased PP may herald an increased propensity for obesity in Maori individuals.

The third key finding of this study was that Maori participants had significantly elevated IL-6 levels in comparison to non-Maori participants. IL-6 is a multifunctional mediator and a member of the cytokine family \[[@R51]\]. IL-6 is best known for its role in the inflammatory response, and also a key mediator implicated in chronic low-grade inflammation and pathogenesis of metabolic dysregulation \[[@R52]-[@R57]\]. Many factors have been demonstrated to alter IL-6 secretion, including hyperglycemia \[[@R14]\], circulating PP levels \[[@R15]\] and presence of metabolic disorders \[[@R58]-[@R60]\]. Elevated fasting IL-6 is also associated with both general obesity \[[@R61]\] and abdominal obesity \[[@R13], [@R54]\], due to the increased secretion of IL-6 from excess adipose tissue \[[@R62]\]. Further, Vozarova et al \[[@R63]\] demonstrated that IL-6 is associated with increased body fat, fat mass and waist circumference in Pima Indians. In our study, we found that fasting IL-6 levels were increased in Maori individuals across all statistical models that controlled for covariates known to influence IL-6 levels (including but not limited to BMI and DM status) \[[@R13], [@R14], [@R61]\]. The findings of this study suggest that Maori individuals experience an amplified chronic low-grade inflammatory response compared to non-Maori individuals. However, due to the pluripotent nature of IL-6, the clinical implications of the cross-talk between IL-6 and obesity in Maori needs to be investigated in future studies. Further, IL-6 was not controlled for ghrelin or PP levels; therefore, it cannot be ruled out that IL-6 is elevated in response to the increased secretion of these two hormones. Prospective studies are now warranted to understand the interactions of IL-6 with gut and pancreatic hormones, which may elucidate its function in pathogenesis of obesity in Maori individuals.

There are several limitations to this study. First, given the cross-sectional design, no inferences can be drawn as to whether ghrelin, PP and IL-6 are causes or consequences of obesity in Maori individuals. A prospective longitudinal study is now warranted to determine whether Maori individuals have a higher predisposition to increased circulating levels of certain hormones and pro-inflammatory cytokines. Second, all studied hormones and pro-inflammatory cytokines were measured in fasting state. Given that certain gut and pancreatic hormones are secreted postprandially, future studies should use mixed meal test \[[@R64]\] to determine whether circulating levels of the studied hormones are altered in Maori individuals. Nonetheless, the present study allowed us to rule out the effect of nutrition, suggesting that other factors are also responsible for the altered hormonal secretion \[[@R65]-[@R67]\]. Third, this study did not investigate genetic variations between ethnicities; therefore, congenital differences in hormone secretion related to ethnicity cannot be ruled out. Future studies are warranted to determine if differences in hormone and pro-inflammatory cytokine secretion stem from genetic variations that may occur between ethnicities. Fourth, all participants in this study had a history of an attack of acute pancreatitis. However, the course of disease was mild to moderate in the majority of study participants and blood samples were collected, on average, in nearly 2 years since an attack. Further, the multi-level statistical modelling, including pancreatitis-related factors, ensured the most robust and conservative output \[[@R68]\]. Last, the study included a limited number of Maori individuals due to the *post-hoc* nature of the analysis. Hence, the findings of this study should be treated as preliminary to justify a larger purposely-designed prospective study that specifically investigates profile of gut hormones, pancreatic hormones and pro-inflammatory cytokines in Maori, as well as its relation to obesity and DM.

In conclusion, this study suggests that Maori individuals may have significantly altered levels of ghrelin, PP and IL-6, even after controlling for BMI, DM status and other covariates. Further research is needed to investigate clinical and public health implications of these findings. Identifying pathophysiological differences in the development of obesity may contribute towards improving health outcomes in this ethnic group.
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